India · Delayed Price · Currency is INR Concord Biotech Statistics
Total Valuation
Concord Biotech has a market cap or net worth of INR 143.20 billion. The enterprise value is 138.88 billion.
| Market Cap | 143.20B |
| Enterprise Value | 138.88B |
Important Dates
The next estimated earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Jul 24, 2026 |
Share Statistics
| Current Share Class | 104.62M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.29% |
| Shares Change (QoQ) | +1.02% |
| Owned by Insiders (%) | 60.87% |
| Owned by Institutions (%) | 15.00% |
| Float | 26.62M |
Valuation Ratios
The trailing PE ratio is 52.00 and the forward PE ratio is 38.96.
| PE Ratio | 52.00 |
| Forward PE | 38.96 |
| PS Ratio | 12.92 |
| PB Ratio | 7.11 |
| P/TBV Ratio | 7.11 |
| P/FCF Ratio | 83.39 |
| P/OCF Ratio | 53.66 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 34.12, with an EV/FCF ratio of 80.87.
| EV / Earnings | 50.43 |
| EV / Sales | 12.53 |
| EV / EBITDA | 34.12 |
| EV / EBIT | 42.39 |
| EV / FCF | 80.87 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 1,245.02 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 15.35% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 6.83M |
| Profits Per Employee | 1.70M |
| Employee Count | 1,624 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Concord Biotech has paid 913.90 million in taxes.
| Income Tax | 913.90M |
| Effective Tax Rate | 25.09% |
Stock Price Statistics
The stock price has decreased by -15.65% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -15.65% |
| 50-Day Moving Average | 1,451.74 |
| 200-Day Moving Average | 1,270.20 |
| Relative Strength Index (RSI) | 39.27 |
| Average Volume (20 Days) | 12,174 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Biotech had revenue of INR 11.08 billion and earned 2.75 billion in profits. Earnings per share was 26.24.
| Revenue | 11.08B |
| Gross Profit | 7.16B |
| Operating Income | 3.25B |
| Pretax Income | 3.64B |
| Net Income | 2.75B |
| EBITDA | 4.03B |
| EBIT | 3.25B |
| Earnings Per Share (EPS) | 26.24 |
Balance Sheet
The company has 4.32 billion in cash and 23.16 million in debt, with a net cash position of 4.30 billion.
| Cash & Cash Equivalents | 4.32B |
| Total Debt | 23.16M |
| Net Cash | 4.30B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 20.15B |
| Book Value Per Share | 192.81 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 2.67 billion and capital expenditures -951.51 million, giving a free cash flow of 1.72 billion.
| Operating Cash Flow | 2.67B |
| Capital Expenditures | -951.51M |
| Depreciation & Amortization | 775.84M |
| Net Borrowing | -6.54M |
| Free Cash Flow | 1.72B |
| FCF Per Share | n/a |
Margins
Gross margin is 64.57%, with operating and profit margins of 29.32% and 24.84%.
| Gross Margin | 64.57% |
| Operating Margin | 29.32% |
| Pretax Margin | 32.86% |
| Profit Margin | 24.84% |
| EBITDA Margin | 36.32% |
| EBIT Margin | 29.32% |
| FCF Margin | 16.28% |
Dividends & Yields
This stock pays an annual dividend of 7.55, which amounts to a dividend yield of 0.55%.
| Dividend Per Share | 7.55 |
| Dividend Yield | 0.55% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.29% |
| Shareholder Yield | 0.26% |
| Earnings Yield | 1.92% |
| FCF Yield | 1.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Concord Biotech is 1,550.60, which is 13.39% higher than the current price. The consensus rating is "Buy".
| Price Target | 1,550.60 |
| Price Target Difference | 13.39% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 21.06% |
| EPS Growth Forecast (3Y) | 28.36% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |